EIF4EBP1 and esophageal cancer: Similarly, p-4EBP1 underexpression was a beneficial indicator of 5-year overall survival among patients with esophageal cancer (P = 0.0005), nasopharyngeal cancer (P = 0.0005), pancreatic cancer (P = 0.001), and other types (P = 0.01).